Mobilization of monocytic myeloid-derived suppressor cells is regulated by PTH1R activation in bone marrow stromal cells

Abstract

Myeloid-derived suppressor cells (MDSCs) are bone marrow (BM)-derived immunosuppressive cells in the tumor microenvironment, but the mechanism of MDSC mobilization from the BM remains unclear. We investigated how BM stromal cell activation by PTH1R contributes to MDSC mobilization. PTH1R activation by parathyroid hormone (PTH) or PTH-related peptide (PTHrP), a tumor-derived counterpart, mobilized monocytic (M-) MDSCs from murine BM without increasing immunosuppressive activity. In vitro cell-binding assays demonstrated that α4β1 integrin and vascular cell adhesion molecule (VCAM)-1, expressed on M-MDSCs and osteoblasts, respectively, are key to M-MDSC binding to osteoblasts. Upon PTH1R activation, osteoblasts express VEGF-A and IL6, leading to Src family kinase phosphorylation in M-MDSCs. Src inhibitors suppressed PTHrP-induced MDSC mobilization, and Src activation in M-MDSCs upregulated two proteases, ADAM-17 and MMP7, leading to VCAM1 shedding and subsequent disruption of M-MDSC tethering to osteoblasts. Collectively, our data provide the molecular mechanism of M-MDSC mobilization in the bones of tumor hosts.

References

[1] Jeong HM, Cho SW, Park SI. Osteoblasts are the centerpiece of the metastatic bone microenvironment. Endocrinol. Metab. (Seoul.), 2016, 31: 485-492

[2] Buenrostro D, Park SI, Sterling JA. Dissecting the role of bone marrow stromal cells on bone metastases. Biomed. Res. Int., 2014, 2014: 875305

[3] Park SI, Soki FN, McCauley LK. Roles of bone marrow cells in skeletal metastases: no longer bystanders. Cancer Microenviron., 2011, 4: 237-246

[4] Gabrilovich DI. Myeloid-derived suppressor cells. Cancer Immunol. Res., 2017, 5: 3-8

[5] Gros A et al. Myeloid cells obtained from the blood but not from the tumor can suppress T-cell proliferation in patients with melanoma. Clin. Cancer Res., 2012, 18: 5212-5223

[6] Weide B et al. Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or Melan-A-Specific T Cells. Clin. Cancer Res., 2014, 20: 1601-1609

[7] Lim J-Y et al. Ex vivo generated human cord blood myeloid-derived suppressor cells attenuate murine chronic graft-versus-host diseases. Biol. Blood Marrow Transpl., 2018, 24: 2381-2396

[8] Marvel D, Gabrilovich DI. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J. Clin. Invest., 2015, 125: 3356-3364

[9] Bronte V et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat. Commun., 2016, 7

[10] Veglia F, Perego M, Gabrilovich D. Myeloid-derived suppressor cells coming of age. Nat. Immunol., 2018, 19: 108-119

[11] Dolcetti L et al. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur. J. Immunol., 2010, 40: 22-35

[12] Marigo I et al. Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity, 2010, 32: 790-802

[13] Luyckx A et al. G-CSF stem cell mobilization in human donors induces polymorphonuclear and mononuclear myeloid-derived suppressor cells. Clin. Immunol., 2012, 143: 83-87

[14] Lee C-R, Lee W, Cho SK, Park S-G. Characterization of multiple cytokine combinations and TGF-β on differentiation and functions of myeloid-derived suppressor cells. Int. J. Mol. Sci., 2018, 19: 869

[15] Tu S et al. Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell, 2008, 14: 408-419

[16] Svoronos N et al. Tumor cell-independent estrogen signaling drives disease progression through mobilization of myeloid-derived suppressor cells. Cancer Discov., 2017, 7: 72-85

[17] Hegde VL, Nagarkatti M, Nagarkatti PS. Cannabinoid receptor activation leads to massive mobilization of myeloid-derived suppressor cells with potent immunosuppressive properties. Eur. J. Immunol., 2010, 40: 3358-3371

[18] Liang H et al. Host STING-dependent MDSC mobilization drives extrinsic radiation resistance. Nat. Commun., 2017, 8: 1736-10

[19] Park SI et al. Parathyroid hormone-related protein drives a CD11b+Gr1+ cell-mediated positive feedback loop to support prostate cancer growth. Cancer Res., 2013, 73: 6574-6583

[20] Rettig MP, Ansstas G, DiPersio JF. Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4. Leukemia, 2012, 26: 34-53

[21] Shiozawa Y, Pienta KJ, Taichman RS. Hematopoietic stem cell niche is a potential therapeutic target for bone metastatic tumors. Clin. Cancer Res., 2011, 17: 5553-5558

[22] Schmid MC et al. PI3-kinase γ promotes Rap1a-mediated activation of myeloid cell integrin α4β1, leading to tumor inflammation and growth. PLoS One, 2013, 8: e60226

[23] Schmid MC et al. Combined blockade of integrin-α4β1 plus cytokines SDF-1α or IL-1β potently inhibits tumor inflammation and growth. Cancer Res., 2011, 71: 6965-6975

[24] Jin H, Su J, Garmy-Susini B, Kleeman J, Varner J. Integrin alpha4beta1 promotes monocyte trafficking and angiogenesis in tumors. Cancer Res., 2006, 66: 2146-2152

[25] Foubert P, Kaneda MM, Varner JA. PI3Kγ activates integrin α4 and promotes immune suppressive myeloid cell polarization during tumor progression. Cancer Immunol. Res., 2017, 5: 957-968

[26] Xu J et al. Tpl2 protects against fulminant hepatitis through mobilization of myeloid-derived suppressor cells. Front. Immunol., 2019, 10: 1980

[27] Hawila E et al. CCR5 directs the mobilization of CD11b+Gr1+Ly6Clow polymorphonuclear myeloid cells from the bone marrow to the blood to support tumor development. Cell Rep., 2017, 21: 2212-2222

[28] Park S-M, Youn J-I. Role of myeloid-derived suppressor cells in immune checkpoint inhibitor therapy in cancer. Arch. Pharm. Res., 2019, 42: 560-566

[29] Liu Y et al. Targeting myeloid-derived suppressor cells for cancer immunotherapy. Cancer Immunol. Immunother., 2018, 67: 1181-1195

[30] McCauley LK, Martin TJ. Twenty-five years of PTHrP progress: from cancer hormone to multifunctional cytokine. J. Bone Miner. Res., 2012, 27: 1231-1239

[31] Li J et al. PTHrP drives breast tumor initiation, progression, and metastasis in mice and is a potential therapy target. J. Clin. Invest., 2011, 121: 4655-4669

[32] Sato K et al. Passive immunization with anti-parathyroid hormone-related protein monoclonal antibody markedly prolongs survival time of hypercalcemic nude mice bearing transplanted human PTHrP-producing tumors. J. Bone Miner. Res., 1993, 8: 849-860

[33] Sato K, Onuma E, Yocum RC, Ogata E. Treatment of malignancy-associated hypercalcemia and cachexia with humanized anti-parathyroid hormone-related protein antibody. Semin. Oncol., 2003, 30: 167-173

[34] Iguchi H, Aramaki Y, Maruta S, Takiguchi S. Effects of anti-parathyroid hormone-related protein monoclonal antibody and osteoprotegerin on PTHrP-producing tumor-induced cachexia in nude mice. J. Bone Min. Metab., 2006, 24: 16-19

[35] Camirand A, Fadhil I, Luco A-L, Ochietti B, Kremer RB. Enhancement of taxol, doxorubicin and zoledronate anti-proliferation action on triple-negative breast cancer cells by a PTHrP blocking monoclonal antibody. Am. J. Cancer Res., 2013, 3: 500-508

[36] Liang W et al. Antitumor activity of targeting SRC kinases in endothelial and myeloid cell compartments of the tumor microenvironment. Clin. Cancer Res., 2010, 16: 924-935

[37] Mao L et al. Inhibition of SRC family kinases reduces myeloid-derived suppressor cells in head and neck cancer. Int. J. Cancer, 2017, 140: 1173-1185

[38] Yu G-T et al. Inhibition of SRC family kinases facilitates anti-CTLA4 immunotherapy in head and neck squamous cell carcinoma. Cell. Mol. Life Sci., 2018, 75: 4223-4234

[39] Garton KJ et al. Stimulated shedding of vascular cell adhesion molecule 1 (VCAM-1) is mediated by tumor necrosis factor-alpha-converting enzyme (ADAM 17). J. Biol. Chem., 2003, 278: 37459-37464

[40] Lévesque JP, Takamatsu Y, Nilsson SK, Haylock DN, Simmons PJ. Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor. Blood, 2001, 98: 1289-1297

[41] Lévesque J-P et al. Mobilization by either cyclophosphamide or granulocyte colony-stimulating factor transforms the bone marrow into a highly proteolytic environment. Exp. Hematol., 2002, 30: 440-449

[42] Datta NS, Chen C, Berry JE, McCauley LK. PTHrP signaling targets cyclin D1 and induces osteoblastic cell growth arrest. J. Bone Miner. Res., 2005, 20: 1051-1064

[43] Koh AJ, Beecher CA, Rosol TJ, McCauley LK. 3‘,5’-Cyclic adenosine monophosphate activation in osteoblastic cells: effects on parathyroid hormone-1 receptors and osteoblastic differentiation in vitro. Endocrinology, 1999, 140: 3154-3162

[44] Lee C et al. Dual targeting c-met and VEGFR2 in osteoblasts suppresses growth and osteolysis of prostate cancer bone metastasis. Cancer Lett., 2018, 414: 205-213

[45] Jung Y et al. Annexin II expressed by osteoblasts and endothelial cells regulates stem cell adhesion, homing, and engraftment following transplantation. Blood, 2007, 110: 82-90

[46] Shiozawa Y et al. Annexin II/annexin II receptor axis regulates adhesion, migration, homing, and growth of prostate cancer. J. Cell. Biochem., 2008, 105: 370-380

Funding

National Research Foundation (NRF)(2018R1D1A1B07050329)

National Cancer Center (NCC)(HA17C0040)

Korea University Research Grants